Wall Street Zen Elevates Rapport Therapeutics to “Hold” Rating

Rapport Therapeutics (NASDAQ:RAPP) received an upgrade from Wall Street Zen, moving from a “sell” rating to a “hold” rating, as announced in an investor note on Sunday. This change reflects a growing interest in the company’s potential as it continues to navigate the biopharmaceutical landscape.

Several analysts have provided insights into Rapport Therapeutics’ stock performance recently. Notably, Wells Fargo & Company set a price target of $51.00 on December 19, while BTIG Research reaffirmed a “buy” rating with a target price of $47.00 on December 8. Conversely, Weiss Ratings maintained a “sell (d-)” rating during a report released on December 19. The Goldman Sachs Group echoed the positive sentiment by reiterating a “buy” rating on the same date. Additionally, HC Wainwright raised its price target from $34.00 to $40.00, also assigning a “buy” rating.

The consensus among analysts indicates a strong interest in the stock, with seven research analysts categorizing it as a “buy” and one viewing it as a “sell.” According to data from MarketBeat.com, Rapport Therapeutics currently holds an average rating of “Moderate Buy” and an average price target of $48.33.

Recent Financial Performance and Insider Activity

Rapport Therapeutics recently reported its quarterly earnings results on November 6, revealing an earnings per share (EPS) of -$0.71. This figure exceeded analysts’ expectations, which had predicted an EPS of -$0.77. For the current fiscal year, projections suggest the company will post an average EPS of -3.65.

In related news, CEO Abraham Ceesay sold 5,083 shares of the company on January 20 at an average price of $26.11, totaling approximately $132,717.13. Following this transaction, Ceesay holds 25,812 shares, valued at around $673,951.32, marking a 16.45% decrease in ownership. This sale was disclosed in a filing with the U.S. Securities and Exchange Commission (SEC).

Similarly, insider David Bredt sold 8,500 shares on January 15 for an average price of $26.84, which amounted to about $228,140.00. After this transaction, Bredt retains 395,575 shares valued at approximately $10,617,233, reflecting a 2.10% decrease in ownership. Over the past three months, insiders have sold a total of 67,655 shares valued at $1,863,705. Company insiders now own 13.57% of the company’s stock.

Institutional Investor Activity

Rapport Therapeutics has seen increased activity among institutional investors recently. Baker BROS. Advisors LP expanded its stake by 181.2% during the third quarter, acquiring an additional 997,000 shares, bringing its total to 1,547,090 shares valued at $45,949,000. Additionally, Vestal Point Capital LP entered a new position valued at $28,215,000 during the same period.

Other significant transactions include Polar Capital Holdings Plc purchasing shares worth $27,887,000 and Capital International Investors increasing its holdings by 30.7%, now owning 3,402,529 shares valued at $101,055,000. Lastly, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position by 265.9%, acquiring 892,258 shares valued at $26,500,000.

About Rapport Therapeutics

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing targeted therapies for cancer patients. The company utilizes a proprietary discovery engine to identify novel tumor-associated antigens, creating tailored biologic and small-molecule candidates that aim to modulate essential oncogenic pathways. With a pipeline that includes multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine and addressing unmet needs in oncology.

The company’s innovative approach integrates high-throughput screening, molecular profiling, and in vivo validation to expedite the progression of lead candidates from the laboratory to clinical evaluation.